— Robert G. Allen
PR Newswire Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...
PR Newswire NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate...
Published: Jul 20, 2022 Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth quarter of 2022 NEW YORK, July 20,...
Paid content by: 👋 Welcome Video 📹 Play Me ⬇️ 👋 Hey Boardroom Members, You’ve heard that saying it’s not what you know…it’s who you know. Before we dive into our mystery company today, I’d like to tell you a little story about the humble beginnings of a...
Sponsored by: 👋 Welcome Video 📹 👋 Hey Boardroom Members, In the Founder Focus series I’ve tried to bring you an eclectic bunch of stories of people who founded companies in all sorts of industries. Often these stories center around...
Sponsored by MYMD See Disclosure Below Hello, I hope you have been paying attention to what has been happening with MYMD lately? It is the very first company that we have chosen to work with directly and share with our audience. As you can imagine, I get a...
Sponsored by: Is a squeeze coming on MYMD soon? Let’s dig in. ⛏ In 360 Wall Street, we do a lot of momentum trading. One of the big things we look for is positively stacked EMAs. (Exponential Moving Averages) Momentum tends to play out over a few...